by Shana Cristoferi | Mar 18, 2020 | IMV Inc., News
See original release here FOR IMMEDIATE RELEASE Dartmouth, Nova Scotia, March 18, 2020 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based...
by Shana Cristoferi | Sep 13, 2019 | News
Read original article here IMV Inc., the Dartmouth company developing a delivery platform for immunotherapy drugs, is entering a critical phase of its 16-year history as it will soon learn the results of key Phase 2 clinical trials. The company is conducting a range...
by Shana Cristoferi | Sep 5, 2019 | IMV Inc., News
Read original article here September 4, 2019 at 7:05 AM EDT DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–Sep. 4, 2019– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and...
by Shana Cristoferi | Jun 27, 2019 | Appili Therapeutics, IMV Inc., News, SONA NanoTech
Read full Entrevestor article here The stock market is looming larger in the Atlantic Canadian startup community than it ever has before, as several leading companies are choosing public markets as the best option to secure long-term financing. Just in the past week,...
